Page 3 - Sun Pharma

Churning portfolio ahead of Diwali? Ambit lists top 10 'winning' stocks

Ambit analysts see HDFC Bank benefiting from accelerating credit growth, normalisation in cost of funds, and focus on high-yield segments like MSME, gold, and unsecured retail loans.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Sun Pharma hit by US tariff risk, but earnings impact to remain limited

The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report. The US last week announced the imposition of a 100 per cent tariff on branded or patented drugs entering the United States from October 1, except for pharmaceutical companies building manufacturing plants in the US. The exemption covers projects where construction has started, including sites that have broken ground or are under construction. HSBC said Sun Pharma reported global sales of USD 1.217 billion from patented products in FY25, of which the US market accounted for about USD 1.1 billion (85-90 per cent of global sales),

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Sun Pharmaceutical: Domestic, innovation push eyed; Nuvama maintains 'Hold'

Sun Pharma aims to strengthen its domestic formulations business through field force expansion and a generic GLP-1 launch in CY26.

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Stocks to watch today, Sep 10: Bajaj Auto, TaMo, Sun Pharma, Eicher, BEL

Stocks to watch on Wednesday, September 10, Bajaj Auto: To fully pass on GST cut benefits; price reduction up to ₹20,000 on bikes and ₹24,000 on three-wheelers from September 22.

Sun Pharma stock concerns may be overstated as domestic growth holds

Analysts say Sun Pharma's stock concerns are overdone, with strong domestic growth, broad-based chronic portfolio gains and resilient Q1FY26 earnings offsetting US market worries

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

US FDA has classified Sun Pharma's Halol facility in Gujarat as OAI, keeping it under import alert, signalling possible enforcement action unless corrective steps are taken

Sun Pharma stock slips 2% in firm market, nears 52-week low; here's why

Thus far in the calendar year 2025, Sun Pharma stock has underperformed the market by falling nearly 17 per cent, as compared to 2 per cent rise in the BSE Sensex.

Sun Pharma slips 5% in 2 days, nears 52-wk low; why drug stock trades weak?

Thus far in August 2025, Sun Pharma has underperformed the market by falling 8 per cent, as compared to a 1 per cent decline in the BSE Sensex

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Sensex down 260 pts, Nifty below 24,700; FMCG lead gains, pharma drags

Majority of stocks from the Sensex pack were trading in red with Sun Pharma, Tata Steel, Tata Motors, Infosys and Tech Mahindra among the top laggards.

Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%

Litigation, drug discontinuation weigh on earnings; US market remains sluggish even as India sales and Leqselvi launch boost specialty push

Sun Pharma Q1 results: PAT dips 20% to ₹2,279 crore; revenue rises 8.6%

Sun Pharmaceutical Industries on Thursday said its consolidated net profit declined 20 per cent year-on-year to Rs 2,279 crore for the first quarter ended June 30, 2025. The Mumbai-based drug major posted a net profit of Rs 2,836 crore for the April-June quarter of the last financial year. Adjusted net profit, excluding the exceptional items, for the first quarter stood at Rs 2,996 crore, up 6 per cent year-on-year. Total income rose to 14,316 crore for the June quarter as against Rs 13,185 crore in the year-ago period, Sun Pharma said in a regulatory filing. Sun Pharma Chairman and Managing Director Dilip Shanghvi said the drug maker had a strong performance during the quarter, where the overall growth reflects steady progress across all its markets. "India continues to show strong momentum, contributing meaningfully to our performance. The US launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata," he ...

Here's why Apollo Hospitals & 2 other stocks are on analyst radar today

Stocks to buy: Analyst at Religare recommends Sun Pharma, Apollo Hospitals; Check target price, stop loss here